Sponsors (12)
The bill increases national-security protection by restricting export of sensitive synthetic genetic data, at the trade-off of higher compliance costs, delays, and regulatory uncertainty that could slow research, burden startups and institutions, and raise taxpayer-administered enforcement costs.
Scientists, biotech firms, and the public face a lower risk that synthetic DNA/RNA designs and sensitive bio-design data will be accessed or exploited by hostile foreign governments or actors because of tighter export controls.
Researchers and companies gain regulatory predictability because the bill directs Commerce to create a clear legal framework and a 1-year deadline to regulate potentially high‑risk bio-design data.
Researchers and firms retain access to information already considered publicly available or benign because the bill exempts data covered by 15 C.F.R. § 734.3(b), reducing unnecessary duplication of controls.
Academic labs, biotech companies, and startups will face higher compliance costs and potential delays exporting sequence files and related data to collaborators, slowing projects and raising operational expenses.
Researchers and students will likely see reduced international collaboration and slower legitimate biomedical innovation if licensing requirements are onerous or approvals are delayed.
Ambiguous definitions (e.g., scope of 'digital sequence' or 'foreign entity of concern') will create compliance uncertainty for labs and startups, increasing legal and administrative burdens and raising the risk of uneven enforcement.
Based on analysis of 3 sections of legislative text.
Requires federal export licenses for digital sequences of synthetic DNA/RNA sent to designated foreign entities of concern, with Commerce to implement rules within one year.
Official title: To restrict the export to foreign entities of concern of United States intellectual property and sensitive information related to synthetic biology, and for other purposes.
Introduced December 11, 2025 by Warren Davidson · Last progress December 11, 2025
The bill requires a federal export license for transfers to specified foreign governments or entities of digital DNA or RNA sequences (including sequences designed by humans or AI) and directs the Commerce Secretary to put the licensing regime into effect within one year. It frames the policy as a national security response to the People’s Republic of China’s access to sensitive U.S. biological data and intellectual property. The measure defines key terms (digital sequence, synthetic DNA/RNA, foreign entity/country of concern) and excludes certain material already covered by existing Commerce Department rules; it amends the Export Control Reform Act to add this licensing requirement for exports, reexports, and in-country transfers to foreign entities of concern.